Recent exceptional negative changes in investment behavior have affected Teva Pharmaceutical Industries L (NYSE: TEVA): negative upside/downside volume developed, and its shorter term price trend turned down.
Teva Pharmaceutical Industries L (NYSE: TEVA) suffers from notable negative changes in fundamentals: the stock’s power rating fell below 50, and significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Teva Pharmaceutical Industries L has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Teva Pharmaceutical Industries L has a good Appreciation Score of 74 but a neutral Power Rating of 48, resulting in the High Neutral Value Trend Rating.
Recent Price Action
On 2/28/25, Teva Pharmaceutical Industries L (NYSE: TEVA) stock rose modestly by 0.9%, closing at $16.46. However, below average trading volume at 79% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months but has declined -3.2% during the last week.
Be the first to comment